LLY

1,053.95

+4.48%↑

JNJ

245.58

+1.27%↑

ABBV

229.45

+2.09%↑

NVS

164.49

+1.11%↑

MRK

123.71

+1.19%↑

LLY

1,053.95

+4.48%↑

JNJ

245.58

+1.27%↑

ABBV

229.45

+2.09%↑

NVS

164.49

+1.11%↑

MRK

123.71

+1.19%↑

LLY

1,053.95

+4.48%↑

JNJ

245.58

+1.27%↑

ABBV

229.45

+2.09%↑

NVS

164.49

+1.11%↑

MRK

123.71

+1.19%↑

LLY

1,053.95

+4.48%↑

JNJ

245.58

+1.27%↑

ABBV

229.45

+2.09%↑

NVS

164.49

+1.11%↑

MRK

123.71

+1.19%↑

LLY

1,053.95

+4.48%↑

JNJ

245.58

+1.27%↑

ABBV

229.45

+2.09%↑

NVS

164.49

+1.11%↑

MRK

123.71

+1.19%↑

Начало・Списък с акции・Pliant Therapeutics Inc

Pliant Therapeutics Inc

Затворен

1.22 -4.69

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

1.21

Максимум

1.28

Ключови измерители
By Trading Economics
Приходи	17M -26M
Служители	171
EBITDA	19M -23M

Дивиденти
By Dow Jones
Следващи печалби	26.02.2026 г.

Пазарни показатели
By TradingEconomics
Пазарна капитализация	-34M 68M
Предишно отваряне	5.91
Предишно затваряне	1.22

Техническа оценка

By Trading Central

Увереност

Very Strong Bearish Evidence

1.43 / 1.6 Подкрепа & съпротива

Pliant Therapeutics Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

23.02.2026 г., 22:53 ч. UTC

Придобивния, сливания и поглъщания

Keurig Dr Pepper Raises Additional $1.5 Billion in Deal to Split Company

23.02.2026 г., 22:36 ч. UTC

Печалби

Kratos Defense & Security Solutions 4Q Profit Rises; Sees Federal Shutdown Denting 1Q -- Update

23.02.2026 г., 22:32 ч. UTC

Печалби

Woodside Energy Fiscal Year Net Profit Falls 24%

23.02.2026 г., 23:58 ч. UTC

Пазарно говорене

Печалби

Plenty of Questions for Woodside Despite Well-Guided Result -- Market Talk

23.02.2026 г., 23:58 ч. UTC

Пазарно говорене

Печалби

Global Energy Roundup: Market Talk

23.02.2026 г., 23:47 ч. UTC

Пазарно говорене

Scentre's Share Price Slips as Earnings Guidance Underwhelms -- Market Talk

23.02.2026 г., 23:43 ч. UTC

Пазарно говорене

Gold Edges Higher Amid Ongoing Tariff Risks -- Market Talk

23.02.2026 г., 23:41 ч. UTC

Придобивния, сливания и поглъщания

Crescent Capital Partners Owns 53% of ClearView Wealth

23.02.2026 г., 23:40 ч. UTC

Придобивния, сливания и поглъщания

ClearView Wealth Says Crescent Capital Partners Intends to Support Deal

23.02.2026 г., 23:40 ч. UTC

Придобивния, сливания и поглъщания

ClearView Wealth Says Directors Unanimously Recommend Shareholders Vote in Favor of Deal

23.02.2026 г., 23:40 ч. UTC

Пазарно говорене

Nikkei May Rise as Investors Assess Tariff Developments -- Market Talk

23.02.2026 г., 23:40 ч. UTC

Придобивния, сливания и поглъщания

ClearView Wealth Says Zurich Insurance Offering A$0.65/Share in Cash

23.02.2026 г., 23:39 ч. UTC

Придобивния, сливания и поглъщания

ClearView Wealth Agrees to Takeover by Zurich Insurance Group Unit

23.02.2026 г., 23:31 ч. UTC

Печалби

United Overseas Bank 2025 Total Dividend S$1.56/Shr >U11.SG

23.02.2026 г., 23:31 ч. UTC

Печалби

United Overseas Bank Proposes Final Dividend of S$0.71/Shr Vs. S$0.92/Shr >U11.SG

23.02.2026 г., 23:28 ч. UTC

Печалби

United Overseas Bank 4Q Net Interest Income S$2.35B Vs. S$2.45B >U11.SG

23.02.2026 г., 23:28 ч. UTC

Печалби

United Overseas Bank 4Q Oper Pft S$1.76B Vs. Pft S$1.88B >U11.SG

23.02.2026 г., 23:28 ч. UTC

Печалби

United Overseas Bank 4Q Total Income S$3.29B Vs. S$3.46B >U11.SG

23.02.2026 г., 23:27 ч. UTC

Печалби

United Overseas Bank 4Q Net S$1.41B Vs. Net S$1.52B >U11.SG

23.02.2026 г., 23:24 ч. UTC

Пазарно говорене

Major Miners On Whole Delivered Positive Earnings Season -- Market Talk

23.02.2026 г., 22:38 ч. UTC

Придобивния, сливания и поглъщания

Keurig Dr Pepper Raises Additional $1.5B in Deal to Split Company

23.02.2026 г., 22:31 ч. UTC

Печалби

Hims & Hers Stock Falls. Why Earnings Are Underwhelming Investors. -- Barrons.com

23.02.2026 г., 22:24 ч. UTC

Печалби

Viva Energy Energy & Infrastructure Ebitda A$93 Million

23.02.2026 г., 22:22 ч. UTC

Печалби

Viva Energy FY Commercial & Industrial Ebitda A$460.5 Million

23.02.2026 г., 22:22 ч. UTC

Печалби

Viva Energy FY Convenience & Mobility Ebitda A$197.4 Million

23.02.2026 г., 22:22 ч. UTC

Печалби

Viva Energy FY Underlying Ebitda A$700.9 Million

23.02.2026 г., 22:22 ч. UTC

Печалби

Viva Energy Final Dividend 3.94 Australian Cents/Security

23.02.2026 г., 22:21 ч. UTC

Печалби

Viva Energy FY Revenue A$28.53 Billion, Down 1.1%

23.02.2026 г., 22:21 ч. UTC

Печалби

Viva Energy FY Replacement-Cost Net Profit A$183.6 Million, Down 28%

23.02.2026 г., 22:20 ч. UTC

Печалби

Viva Energy FY Historical-Cost Net Loss A$421.1 Million

Сравнение с други в отрасъла

Ценова промяна

Pliant Therapeutics Inc Прогноза

Консенсусна оценка

By TipRanks

Продай

1 ratings

Купи

Задържане

Продай

Според 1 анализатори, дали борсови рейтинги на Pliant Therapeutics Inc през последните 3 месеца.

Техническа оценка

By Trading Central

1.43 / 1.6Подкрепа & съпротива

Recent bearish events outweigh bullish events.

There is one bearish event.

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно Pliant Therapeutics Inc

Pliant Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. The company's lead candidate is bexotegrast, an oral, small-molecule, dual selective inhibitor of avß6 and avß1 integrins, which is in phase 2b trials for idiopathic pulmonary fibrosis and in phase 2a trial for primary sclerosing cholangitis. It also develops PLN-1474, an oral, small-molecule selective inhibitor of avß1 for the treatment of liver fibrosis associated with nonalcoholic steatohepatitis; PLN-101095, a dual inhibitor of integrins avß8 and avß1 for the treatment of solid tumors; and PLN-101325 for treatment of muscular dystrophies. Pliant Therapeutics, Inc. was incorporated in 2015 and is based in South San Francisco, California.